Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yokogawa Bio Frontier is a wholly owned subsidiary of Yokogawa Electric focused on developing, producing, and commercializing plant-derived biomass materials rather than therapeutics. The company was established in 2021 in Tokyo to build businesses around high-value biomass materials such as nanocellulose and lignin monomers, along with related licensing and consulting services. Its best-described commercial product offering is S-CNF, a sulfated cellulose nanofiber material positioned for use in chemicals, materials, and related industrial applications. Yokogawa Bio Frontier also collaborates with strategic partners such as Bloom Biorenewables to expand lignin-derived biomass opportunities in Japan. Although it may touch end markets that include pharmaceuticals or cosmetics as customers, it is not primarily a life sciences, biotech, pharma, or healthcare company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Yokogawa Bio Frontier.